Simtrazene (centrazene) is an anti-neoplastic compound which is not an alkylating agent. Centrazene was more effective than thioTEPA in prolonging the life span of mice bearing C3H mammary tumors but did not demonstrate activity against other tumor types.

Dofamium is the antiseptic agent. It was used for the water sterilization.

Tanaproget (WAY-166989) is a nonsteroidal progesterone receptor agonist. It has been in Phase-II clinical trials as an oral contraceptive. The compound demonstrated a positive preclinical pharmacological profile in the treatment of endometriosis. The level of progesterone receptors in breast tumours can be used to guide the selection of endocrine therapies for breast cancer patients. Radiolabeled analogues of tanaproget have diagnostic potential as PET imaging agents for breast cancer.

Delfantrine is an analgesic, antiinflammatory agent, developed by Ciba.

Deditonium is an antibacterial compound developed by the French company Centre de Recherches des Laboratoires Diamant. Deditonium is a quaternary ammonium derivative and has a bacteriostatic action at concentrations ranging from 1x10-6 to 5x10-4 M. Gram-positive cocci were found to be the most sensitive as well as many enterobacteria.

Cypothrin is a synthetic pyrethroid insecticide, developed by American Cyanamide for the control of ticks and marketed under the tradename Panecto. The compound exhibited systemic insecticidal activity in the model of flies infestation in mice and ixodicidal activity in against larvae of Boophilus microplus.

Netazepide (YF476) is an orally active, benzodiazepine type, selective cholecystokinin B receptor (CCKBR; CCK2R; gastrin receptor) antagonist with potential gastric acid reducing and antiproliferative activity. Upon administration, netazepide, selectively binds to and blocks the CCKBR, thereby preventing the binding of gastrin and cholecystokinin. This may prevent gastric neuroendocrine enterochromaffin-like (ECL) cell-induced secretion of histamine, ultimately preventing gastric acid secretion from adjacent parietal cells. In addition, YF476 may inhibit ECL cell proliferation and ECL-derived gastric carcinoids. Netazepide has been used in trials studying the prevention and treatment of dyspepsia, hypergastrinaemia, barrett's esophagus, ECL-cell hyperplasia, and rebound hyperacidity, among others. Netazepide once daily for 12 weeks reduced the number of tumours and size of the largest one in 16 patients with autoimmune chronic atrophic gastritis (CAG), achlorhydria, hypergastrinaemia and multiple gastric neuroendocrine tumours (type 1 gastric NETs), and normalized circulating chromogranin A (CgA) produced by enterochromaffin-like cells, the source of the tumours.

Piridicillin is the semi-synthetic penicillin. It has exhibited broad-spectrum activity in vitro against gram-positive cocci, except penicillin G-resistant Staphylococcus aureus, and against gram-negative bacilli. Piridicillin is reported to be more active in-vitro than piperacillin, azlocillin or ticarcillin against Ps. aeruginosa. It is unstable at alkaline pH and displays marked inoculum independence.

ROTAMICILLIN was developed as an antibiotic that has never been marketed.